Arecor Therapeutics PLC ARECOGRANTED PATENT IN JAPAN AND SOUTH KOREA (1358H)
November 22 2022 - 2:00AM
UK Regulatory
TIDMAREC
RNS Number : 1358H
Arecor Therapeutics PLC
22 November 2022
Arecor Therapeutics plc
("Arecor" or the "Group")
ARECOR GRANTED KEY PATENT IN JAPAN AND SOUTH KOREA TO PROTECT
PROPRIETARY INSULIN PRODUCTS AT247 AND AT278
The granted patents further strengthen the Group's extensive
patent portfolio protecting its proprietary Arestat(TM) technology
and diabetes product portfolio
Cambridge, UK, 22 November 2022: Arecor Therapeutics plc (AIM:
AREC), the biopharmaceutical group advancing today's therapies to
enable healthier lives, is pleased to announce that the Japan
Patent Office has granted a patent ( JP7145849) protecting novel
formulations of the Group's proprietary insulin products, AT247 and
AT278. The same patent has also been granted in South Korea.
Dr Jan Jezek, Chief Scientific Officer at Arecor, commented :
"Enabled by our Arestat(TM) technology platform we have two
proprietary insulin product candidates within clinical development
based on novel formulations of existing insulin that have the
potential to bring significant patients to people living with
diabetes. We have demonstrated in Phase I clinical studies that we
have both an ultra-rapid acting insulin (AT247) with the potential
to enable an artificial pancreas system which would be
transformative for patients, as well as an ultra-concentrated
ultra-rapid acting insulin (AT278) which has the potential to
become the gold standard insulin for the growing population of
people with diabetes with high daily insulin needs. With these very
promising profiles, we will be looking to gain market share within
the existing >$6bn prandial global insulin market and, as such,
intellectual property protection of AT247 and AT278 is critical.
The grant of this key patent protecting AT247 and AT278 in Japan
and South Korea, following on from the US patent granted earlier
this year within our insulin IP portfolio, marks an important
milestone in our comprehensive IP strategy as we continue to
maximise the IP protection for our insulin products."
The Arestat(TM) technology enables superior product profiles
across a broad range of pharmaceuticals. Arecor leverages the
technology to develop its own portfolio of superior proprietary
products in diabetes and other indications. In addition, Arecor
partners with leading pharmaceutical and biotechnology companies to
deliver enhanced formulations of their therapeutic products under a
technology licensing model .
Arecor has invested in building a strong patent portfolio to
protect the Arestat(TM) technology platform and the proprietary
pipeline products. The Group's intellectual property (IP) portfolio
currently comprises 36 patent families, including >50 granted
patents in Europe, the US and in other key territories. As part of
this strategy, Arecor has robust IP that protects the novel
compositions of AT247 and AT278, as well as their specific
properties and methods of use. Arecor's strategy is to generate a
fortress of both narrow and broad interrelated IP rights that cover
the key features of these products. The grant of these patents
marks an important milestone within the Group's comprehensive
proprietary insulin product IP strategy.
-ENDS-
For more information, please contact:
Arecor Therapeutics plc www.arecor.com
Dr Sarah Howell, Chief Executive Officer Tel: +44 (0) 1223 426060
Email: info@arecor.com
Susan Lowther, Chief Financial Officer Tel: +44 (0) 1223 426060
Email: info@arecor.com
Mo Noonan, Communications Tel: +44 (0) 7876 444977
Email: mo.noonan@arecor.com
Panmure Gordon (UK) Limited (NOMAD Tel: +44 (0) 20 7886 2500
and Broker)
Freddy Crossley, Emma Earl (Corporate
Finance)
Rupert Dearden (Corporate Broking)
Consilium Strategic Communications
Chris Gardner, David Daley, Angela Tel: +44 (0) 20 3709 5700
Gray Email: arecor@consilium-comms.com
Notes to Editors
About AT247
AT247 is Arecor's ultra-rapid insulin that has been demonstrated
in Phase I clinical studies to accelerate significantly insulin
absorption post injection, and thus enable more effective
management of blood glucose levels for people living with diabetes,
particularly around difficult to manage mealtimes. Such ultra-rapid
acting insulin may facilitate an automated insulin delivery via a
fully closed loop artificial pancreas, a potentially life changing
treatment option for people living with diabetes.
About AT278
AT278 is an ultra-concentrated (500 U/mL) novel formulation of
insulin that has been designed to accelerate the absorption of
insulin post injection, even when delivered at a high
concentration, and hence via a lower injection volume. Currently,
there are no concentrated (>200 U/mL) rapid acting insulin
products on the market and therefore AT278 has the potential to be
the first such product available to patients. It has the potential
to enable more effective management of blood glucose levels to the
increasing number of people with diabetes with high daily insulin
requirements (>200 units/day) whilst maintaining the convenience
and compliance benefits of being able to deliver these high insulin
doses in a lower injection volume via a single injection. In
addition, a truly rapid acting concentrated insulin is also a
critical step towards the advancement and miniaturisation of the
next generation of insulin delivery devices.
About Arecor
Arecor Therapeutics plc is a globally focused biopharmaceutical
company transforming patient care by bringing innovative medicines
to market through the enhancement of existing therapeutic products.
By applying our innovative proprietary formulation technology
platform, Arestat(TM) , we are developing an internal portfolio of
proprietary products in diabetes and other indications, as well as
working with leading pharmaceutical and biotechnology companies to
deliver enhanced formulations of their therapeutic products. The
Arestat (TM) platform is supported by an extensive patent portfolio
.
For further details please see our website, www.arecor.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCFFFFFLELLFIF
(END) Dow Jones Newswires
November 22, 2022 02:00 ET (07:00 GMT)
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Jul 2023 to Jul 2024